Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected personGlobeNewsWire • 11/24/20
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected PersonBusiness Wire • 11/23/20
Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh timeGlobeNewsWire • 11/16/20
CHMP recommends EU approval of Roche's Xofluza® (baloxavir marboxil) for the treatment of influenzaGlobeNewsWire • 11/13/20
CHMP recommends EU approval of Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancerGlobeNewsWire • 11/13/20
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual MeetingBusiness Wire • 11/05/20
European Commission approves Roche's Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancerGlobeNewsWire • 11/02/20
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancerPRNewsWire • 10/29/20
Roche's Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancerGlobeNewsWire • 10/29/20
The Hanover Insurance Group, Inc.'s (THG) CEO Jack Roche on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/29/20
Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patientsGlobeNewsWire • 10/22/20
NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung CancerBusiness Wire • 10/21/20
Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemiaGlobeNewsWire • 10/19/20
Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid LeukemiaBusiness Wire • 10/16/20
Revenge Of The Clones: Roche Takes A Hit From Biosimilars, But Worthwhile Value RemainsSeeking Alpha • 10/16/20
Roche Holding AG (RHHBY) CEO Severin Schwan on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/15/20